| Literature DB >> 32808006 |
Fadi Fakhouri1, Marie Scully2,3, François Provôt4,5, Miquel Blasco6, Paul Coppo5,7, Marina Noris8, Kathy Paizis9,10,11, David Kavanagh12,13, Frédéric Pène5,14,15, Sol Quezada16,17, Alexandre Hertig18, Sébastien Kissling1, Patrick O'Brien19, Yahsou Delmas5,20, Lorenzo Alberio21, Norbert Winer22,23,24,25, Agnès Veyradier5,26,27,28, Spero Cataland29, Véronique Frémeaux-Bacchi30, Chantal Loirat31, Giuseppe Remuzzi8, Vassilis Tsatsaris32.
Abstract
Pregnancy and postpartum are high-risk periods for different forms of thrombotic microangiopathy (TMA). However, the management of pregnancy-associated TMA remains ill defined. This report, by an international multidisciplinary working group of obstetricians, nephrologists, hematologists, intensivists, neonatologists, and complement biologists, summarizes the current knowledge of these potentially severe disorders and proposes a practical clinical approach to diagnose and manage an episode of pregnancy-associated TMA. This approach takes into account the timing of TMA in pregnancy or postpartum, coexisting symptoms, first-line laboratory workup, and probability-based assessment of possible causes of pregnancy-associated TMA. Its aims are: to rule thrombotic thrombocytopenic purpura (TTP) in or out, with urgency, using ADAMTS13 activity testing; to consider alternative disorders with features of TMA (preeclampsia/eclampsia; hemolysis elevated liver enzymes low platelets syndrome; antiphospholipid syndrome); or, ultimately, to diagnose complement-mediated atypical hemolytic uremic syndrome (aHUS; a diagnosis of exclusion). Although they are rare, diagnosing TTP and aHUS associated with pregnancy, and postpartum, is paramount as both require urgent specific treatment.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32808006 DOI: 10.1182/blood.2020005221
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113